Exelixis (EXEL) Q1 2026 Earnings Transcript

Exelixis reported Q1 2026 revenue of $611 million, up on strong cabozantinib performance, with U.S. franchise net product revenue rising 8% year over year to $555 million and global franchise revenue up 12.5% to $764 million. The company posted GAAP net income of $210.5 million and reiterated full-year 2026 guidance while continuing aggressive capital returns, including $430.8 million of buybacks in the quarter and a new $50 million authorization. Management also highlighted progress toward a potential ZANZA launch in colorectal cancer, with a PDUFA date in early December 2026 and multiple pivotal trials advancing across RCC, NETs, and other tumors.

Analysis

The core incremental signal is not the near-term CABOMETYX print; it is that Exelixis is using a mature cash engine to de-risk a second franchise while the market still discounts ZANZA as a binary pipeline story. The combination of accelerated buybacks, a large cash balance, and reiterated guidance gives management optionality to keep compounding per-share value even if the ZANZA launch slips, which should compress downside versus a typical pre-launch biotech.

The bigger second-order effect is competitive pressure in oncology field force allocation. Exelixis is effectively building a GI/RCC commercial platform ahead of launch, which can create an adoption advantage for any approved label expansion because the incremental cost of customer access falls sharply after CABOMETYX. That matters most in the community setting, where prescribing inertia is high; if ZANZA gets approved, the company is not starting from zero but from an already-trained rep base and an entrenched GI relationship map.

The market is probably underpricing the asymmetry around timing. The upside case is not just a December approval, but a sequencing of catalyst density: midyear subgroup data, midyear STELLAR-316 initiation, second-half RCC/NET updates, and year-end PDUFA. The downside is that the stock can be vulnerable to “good but not great” readthrough if investors view the non-clear-cell RCC and MRD CRC programs as too broad or too diffused; that would mainly cap multiple expansion, not necessarily impair the cash-flow story.

Contrarian view: the recent selloff logic around RCC combo disappointment may be overextended. Exelixis is explicitly pivoting from one first-line hypothesis to a franchise-wide portfolio of shots on goal, which reduces dependence on any single regimen. If the market continues to value EXEL as a one-drug company, buybacks can keep absorbing supply while pipeline optionality accumulates into a rerating event.

Key Decisions for Investors

• Long EXEL for 3-6 months into the midyear catalyst window; favorable setup is a cash-flow name with pipeline optionality and active buyback support, implying limited downside versus peers
• Buy EXEL Jan-2027 calls or call spreads; the thesis is that multiple catalysts by year-end can re-rate the stock before full ZANZA commercialization, with defined downside versus outright equity
• Pair trade: long EXEL / short a basket of higher-beta pre-commercial oncology names; EXEL has self-funded development and repurchases, while peers remain more dependent on capital markets and single-asset readthrough
• If EXEL weakens on RCC headline noise, add on dips rather than chase strength; the risk/reward is best when the market is focused on one trial and ignores the cash-return compounding
• Avoid shorting into the PDUFA window unless there is clear evidence of regulatory friction; the combination of launch preparation, cash generation, and buybacks makes squeeze risk asymmetric